Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum beta-lactamase AmpC.

Literature DB >> 21746958

Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum beta-lactamase AmpC.

Hélène Guillon¹, Didier Tande, Hedi Mammeri.

Abstract

Escherichia coli isolate MEV, responsible for a bloodstream infection, was resistant to penicillins, cephalosporins, and ertapenem. Molecular and biochemical characterization revealed the production of a novel, chromosome-borne, extended-spectrum AmpC (ESAC) β-lactamase with a Ser-282 duplication and increased carbapenemase activity. This study demonstrates for the first time that chromosome-borne ESAC β-lactamases can contribute to the emergence of ertapenem resistance in E. coli clinical isolates.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2011 PMID： 21746958 PMCID： PMC3165280 DOI： 10.1128/AAC.01513-10

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

30 in total

1. Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing ampC.

Authors: N Caroff; E Espaze; D Gautreau; H Richet; A Reynaud
Journal: J Antimicrob Chemother Date: 2000-06 Impact factor: 5.790

2. CTX-M expression and selection of ertapenem resistance in Klebsiella pneumoniae and Escherichia coli.

Authors: Delphine Girlich; Laurent Poirel; Patrice Nordmann
Journal: Antimicrob Agents Chemother Date: 2008-11-24 Impact factor: 5.191

3. Occurrence of ST23 complex phylogroup A Escherichia coli isolates producing extended-spectrum AmpC beta-lactamase in a French hospital.

Authors: Lise Crémet; Nathalie Caroff; Cécile Giraudeau; Sandie Dauvergne; Didier Lepelletier; Alain Reynaud; Stéphane Corvec
Journal: Antimicrob Agents Chemother Date: 2010-02-09 Impact factor: 5.191

Review 4. Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues.

Authors: Kenneth S Thomson
Journal: J Clin Microbiol Date: 2010-02-24 Impact factor: 5.948

Review 5. Updated functional classification of beta-lactamases.

Authors: Karen Bush; George A Jacoby
Journal: Antimicrob Agents Chemother Date: 2009-12-07 Impact factor: 5.191

6. Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.

Authors: Hedi Mammeri; Hélène Guillon; François Eb; Patrice Nordmann
Journal: Antimicrob Agents Chemother Date: 2010-08-23 Impact factor: 5.191

7. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.

Authors: Michel Doumith; Matthew J Ellington; David M Livermore; Neil Woodford
Journal: J Antimicrob Chemother Date: 2009-02-20 Impact factor: 5.790

8. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss.

Authors: Dolunay Gülmez; Neil Woodford; Marie-France I Palepou; Shazad Mushtaq; Gokhan Metan; Yusuf Yakupogullari; Sesin Kocagoz; Omrum Uzun; Gulsen Hascelik; David M Livermore
Journal: Int J Antimicrob Agents Date: 2008-03-12 Impact factor: 5.283

9. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered at two Belgian hospitals.

Authors: P Bogaerts; H Rodriguez-Villalobos; C Bauraing; A Deplano; C Laurent; C Berhin; M J Struelens; Y Glupczynski
Journal: Pathol Biol (Paris) Date: 2009-11-04

10. Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli.

Authors: Hedi Mammeri; Patrice Nordmann; Amira Berkani; François Eb
Journal: FEMS Microbiol Lett Date: 2008-03-27 Impact factor: 2.742

8 in total

1. Structural Alteration of OmpR as a Source of Ertapenem Resistance in a CTX-M-15-Producing Escherichia coli O25b:H4 Sequence Type 131 Clinical Isolate.

Authors: Hervé Dupont; Pascaline Choinier; David Roche; Sandine Adiba; Megan Sookdeb; Catherine Branger; Erick Denamur; Hedi Mammeri
Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191

2. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.

Authors: João Pires; Magdalena Taracila; Christopher R Bethel; Yohei Doi; Sara Kasraian; Regula Tinguely; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal: Antimicrob Agents Chemother Date: 2015-09-21 Impact factor: 5.191

3. Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.

Authors: N T Mutters; S Zimmermann; M Kaase; A Mischnik
Journal: Eur J Clin Microbiol Infect Dis Date: 2015-10-03 Impact factor: 3.267

4. Hydrolysis spectrum extension of CMY-2-like β-lactamases resulting from structural alteration in the Y-X-N loop.

Authors: Sandrine Dahyot; Hedi Mammeri
Journal: Antimicrob Agents Chemother Date: 2012-01-09 Impact factor: 5.191

5. Evaluation of carbapenemase screening and confirmation tests with Enterobacteriaceae and development of a practical diagnostic algorithm.

Authors: Florian P Maurer; Claudio Castelberg; Chantal Quiblier; Guido V Bloemberg; Michael Hombach
Journal: J Clin Microbiol Date: 2014-10-29 Impact factor: 5.948